Dem strategist on Trump’s Epstein blowback: ‘You wound this up. You caused this.’ Dark series 'The Institute' adaptation gets ...

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

Notice of the Cambridge biotech's layoffs came less than two weeks after Sage announced it would be acquired by ...

The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.

An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...

Supernus Pharmaceuticals will acquire Sage Therapeutics in a deal worth up to $795 million to gain access to the only postpartum depression pill approved in the United States.

Parts of the Jacob Lake area are under GO evacuation orders, and the North Rim of the Grand Canyon is also evacuating. The fire has grown to more than 40,000 acres.

Sage and partner Biogen (BIIB) eventually submitted a rolling New Drug Application for 217 in MDD and postpartum depression, in 2023, but the FDA granted approval in the latter indication only.

Astellas Pharma Inc. recently created a new role — that of chief research & development officer — and named Cambridge ...

Supernus is buying Sage Therapeutics for $561 million, hoping that it can transform a new postpartum depression drug into a standard of care.